Breast Cancer: Molecular Mechanisms, Diagnosis Techniques and Therapeutic Targets

A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Molecular Targeted Therapy".

Deadline for manuscript submissions: 30 July 2024 | Viewed by 1108

Special Issue Editor


E-Mail Website
Guest Editor
Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA
Interests: breast cancer; Triple Negative Breast Cancer (TNBC); metastatic breast cancer

Special Issue Information

Dear Colleagues,

Breast cancer remains one of the most common cancers affecting women. Its molecular mechanism involves the growth, migration and invasion of cancerous cells due to dysfunctional proteins and pathways at a genetic level. The main subtypes include Luminal A, Luminal B, HER2-enriched and triple-negative breast cancers. Each has different biomarkers and therapeutic responses. Diagnosis techniques include self-examination, mammography, ultrasound, biopsy and genetic testing. These methods help to identify the stage, type and spread of the cancer. The advancements in molecular biology have led to the formation of therapeutic targets such as hormone receptors (estrogen and progesterone receptors), HER2 proteins and BRCA1 and BRCA2 genes. Targeted therapies based on these receptors and genes have shown better results in treatment. Hormone therapy, radiation therapy, chemotherapy, immunotherapy and surgery are some standard treatment options. However, many novel therapeutic strategies are being developed and tested. Although significant progress has been made over the years, continued research is necessary to improve the survival rate and personalized treatment plans.

This Special Issue aims to present a collection of original research articles and reviews that address the use of modern molecular diagnosis techniques and targeted therapies in breast cancer.

Dr. Shipra Gandhi
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • breast cancer
  • triple-negative breast cancer
  • biomarker
  • molecular mechanism
  • diagnosis technique
  • therapeutic target
  • genetic
  • targeted therapies

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Editorial

3 pages, 196 KiB  
Editorial
Novel Biomarkers to Guide Immunotherapy De-Escalation in the Neoadjuvant Setting in Triple-Negative Breast Cancer
by Shipra Gandhi
J. Pers. Med. 2023, 13(9), 1313; https://doi.org/10.3390/jpm13091313 - 27 Aug 2023
Viewed by 850
Abstract
Triple-negative breast cancer (TNBC) has the highest incidence of disease recurrence and distant metastases among breast cancer subtypes, leading to significant rates of morbidity and mortality [...] Full article
Back to TopTop